Ísrael - hebreska - Ministry of Health

teva pharmaceutical industries ltd, israel - atorvastatin as calcium - טבליה - atorvastatin as calcium 40 mg - atorvastatin - atorvastatin - atorvastatin teva is indicated as an adjunct to diet for reduction of elevated total cholesterol ldl- cholesterol apolipoprotein b and triglycerides and to increase hdl cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types iia and iib of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. atorvastatin teva is also indicated to reduce total-c and ldl -c in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. ldl apheresis) or if such treatments are unavailable. pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl

Ísrael - hebreska - Ministry of Health

teva pharmaceutical industries ltd, israel - atorvastatin as calcium - טבליה - atorvastatin as calcium 80 mg - atorvastatin - atorvastatin - atorvastatin teva is indicated as an adjunct to diet for reduction of elevated total cholesterol ldl- cholesterol apolipoprotein b and triglycerides and to increase hdl cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types iia and iib of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. atorvastatin teva is also indicated to reduce total-c and ldl -c in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. ldl apheresis) or if such treatments are unavailable. pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl

Ísrael - hebreska - Ministry of Health

teva pharmaceutical industries ltd, israel - atorvastatin as calcium - טבליה - atorvastatin as calcium 80 mg - atorvastatin - atorvastatin - atorvastatin teva is indicated as an adjunct to diet for reduction of elevated total cholesterol ldl- cholesterol apolipoprotein b and triglycerides and to increase hdl cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types iia and iib of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. atorvastatin teva is also indicated to reduce total-c and ldl -c in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. ldl apheresis) or if such treatments are unavailable. pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl

Ísrael - hebreska - Ministry of Health

teva israel ltd - raloxifene hydrochloride - טבליה - raloxifene hydrochloride 60 mg - raloxifene - raloxifene - - treatment of osteoporosis in post menopausal women. - prevention of osteoporosis in post menopausal women .

Ísrael - hebreska - Ministry of Health

teva israel ltd - raloxifene hydrochloride - טבליה - raloxifene hydrochloride 60 mg - raloxifene - raloxifene - - treatment of osteoporosis in post menopausal women. - prevention of osteoporosis in post menopausal women .

Ísrael - hebreska - Ministry of Health

teva israel ltd - bicalutamide - טבליה - bicalutamide 50 mg - bicalutamide - bicalutamide - for the treatment of advanced prostate cancer in combination with lhrh analog therapy or surgical castration.

Ísrael - hebreska - Ministry of Health

teva israel ltd - bicalutamide - טבליה - bicalutamide 150 mg - bicalutamide - bicalutamide - in patients with locally advanced prostate cancer (t3-t4 any n m0 t1-t2 n+ m0) bicalutamide is indicated as immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy. the management of patients with locally advanced non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable.

Ísrael - hebreska - Ministry of Health

taro pharmaceutical industries ltd - etodolac - טבליות עם שחרור נרחב - etodolac 600 mg - etodolac - etodolac - for the management of signs and symptoms of osteoarthritis and rheumatoid arthritis.

Ísrael - hebreska - Ministry of Health

taro pharmaceutical industries ltd - etodolac - טבליות עם שחרור נרחב - etodolac 500 mg - etodolac - etodolac - for the management of signs and symptoms of osteoarthrities and rheumatoid arthritis.

Ísrael - hebreska - Ministry of Health

taro pharmaceutical industries ltd - etodolac - טבליות עם שחרור נרחב - etodolac 400 mg - etodolac - etodolac - for the management of signs and symptoms of osteoarthrities and rheumatoid arthritis.